cas 13526-66-4|| where to buy 3-Bromo-6-chloroimidazo[1,2-b]pyridazine

Название продукции:3-Bromo-6-chloroimidazo[1,2-b]pyridazine

IUPAC Name:3-bromo-6-chloroimidazo[1,2-b]pyridazine

Упаковочная единица	Доступно для заказа	Цена ($)
CM164495-25g	in stock	Ǖň
CM164495-100g	in stock	ǯźŔ
CM164495-500g	in stock	ƞźƞŭ

Только для использования в НИОКР..

Форма запроса

Химическое название

Номер CAS

Количество*

Необходимые спецификации*
(% пробы, категория материала и т.д.)

Контактное лицо*

Электронная почта*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 13526-66-4 regularly via the above email.

Дополнительные примечания

Verification code*

refresh

: Номер CAS:13526-66-4; Молекулярная формула:C6H3BrClN3; Точка плавления:-; Smiles-код:ClC1=NN2C(Br)=CN=C2C=C1; Плотность:

: Номер в каталоге:CM164495; Молекулярная масса:232.47; Точка кипения:; Номер Mdl:MFCD09027274; Хранение:Store at 2-8°C.

: Imidazopyridazines; Potent IRAK-4 inhibitors have been reported by several groups including some structurally related benzimidazoles as well as alternative fused heterocycles such as the imidazopyridine and imidazopyridazine. Such compounds are reported to have IRAK-1 and IRAK-4 activity with varying degrees of selectivity.

: Taletrectinib; Recently, Nuvation Bio announced positive pooled data from the pivotal Phase 2 TRUST-I and TRUST-II studies at the European Society for Medical Oncology (ESMO). Analysis showed that its small molecule taletrectinib, a new highly selective ROS1/NTRK kinase inhibitor, can cross the patient's blood-brain barrier to treat brain metastases, and nearly 90% of patients with advanced ROS1-positive non-small cell lung cancer (NSCLC) who received treatment had tumor shrinkage. In patients who had never been treated with tyrosine kinase inhibitors (TKIs), disease remission was sustained for nearly 4 years. Nuvation Bio plans to submit a new drug application (NDA) for the drug to the FDA in the fourth quarter of this year.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.